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Abstract
Background: Shoulder complaints are common in primary care and have unfavourable long term prognosis. Our
objective was to evaluate the clinical effectiveness of manipulative therapy of the cervicothoracic spine and the
adjacent ribs in addition to usual medical care (UMC) by the general practitioner in the treatment of shoulder
complaints.
Methods: This economic evaluation was conducted alongside a randomized trial in primary care. Included were
150 patients with shoulder complaints and a dysfunction of the cervicothoracic spine and adjacent ribs. Patients
were treated with UMC (NSAID’s, corticosteroid injection or referral to physical therapy) and were allocated at
random (yes/no) to manipulative therapy (manipulation and mobilization). Patient perceived recovery, severity of
main complaint, shoulder pain, disability and general health were outcome measures. Data about direct and
indirect costs were collected by means of a cost diary.
Results: Manipulative therapy as add-on to UMC accelerated recovery on all outcome measures included. At 26
weeks after randomization, both groups reported similar recovery rates (41% vs. 38%), but the difference between
groups in improvement of severity of the main complaint, shoulder pain and disability sustained. Compared to the
UMC group the total costs were higher in the manipulative group (€1167 vs. €555). This is explained mainly by the
costs of the manipulative therapy itself and the higher costs due sick leave from work. The cost effectiveness ratio
showed that additional manipulative treatment is more costly but also more effective than UMC alone. The cost-
effectiveness acceptability curve shows that a 50%-probability of recovery with AMT within 6 months after initiation
of treatment is achieved at €2876.
Conclusion: Manipulative therapy in addition to UMC accelerates recovery and is more effective than UMC alone
on the long term, but is associated with higher costs.
International Standard Randomized Controlled Trial Number Register: ISRCTN11216
Background
Shoulder complaints are common. In a recent cross-sec-
tional study 21% of the general population reported
shoulder complaints [1]. Shoulder complaints are char-
acterized by functional disability, most often due to
shoulder pain or to restricted range of motion in the
shoulder. This results in substantial consumption of
medical health care, sick leave from work and disability
in daily living [1,2]. In the Netherlands, general practi-
tioners treat shoulder complaints according to the
National Guidelines of the Dutch College of General
Practitioners [3,4]. This treatment is beneficial on the
short term, but cannot prevent an unfavourable long
term prognosis: only 50% of all new episodes of
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12 months still over 40% of all patients are disabled dur-
ing work and leisure time [5,6].
Musculoskeletal disorders are the second most expen-
sive group for health care costs in the Netherlands.
Shoulder complaints constitute the third most largest
group of musculoskeletal disorders [7]. Insurance data
from Sweden indicate that 18% of disability payments
made for musculoskeletal disorders are spent on
shoulder complaints [8]. Therefore, there is a need for
investigating the cost-of-illness of treatment of shoulder
complaints. We conducted an economic evaluation
alongside a randomized trial. The objective was to eval-
uate the clinical effectiveness of manipulative therapy of
the cervicothoracic spine and the adjacent ribs in addi-
tion to usual medical care (UMC) by the general practi-
tioner in the treatment of shoulder complaints
compared to UMC alone. The design of the study and
the clinical outcomes are reported elsewhere [9,10]. The
study was approved by the Medical Ethical Committee
of the University Medical Centre Groningen.
Methods
Participants and randomization
Potential eligible participants with shoulder complaints
were recruited in 50 general practices in the province of
Groningen, The Netherlands. At presentation the gen-
eral practitioner checked the criteria for eligibility,
informed the researcher (GJDB) of each eligible patient,
and initiated treatment (UMC). The general practitioner
used a standardized eligibility checklist and a physical
examination as recommended by the practice guidelines
f o rs h o u l d e rd i s o r d e r si s s u e db yt h eD u t c hC o l l e g eo f
General Practitioners [4,11]. A baseline assessment at
the research centre was scheduled within two weeks of
presentation. Shoulder complaints were defined as pain
at rest or during movement of the upper arm in the
area between the neck and the elbow. There was no
limitation in the duration of complaints at first presen-
tation, while radiating pain to the neck-region or to the
lower part of the arm was no reason to exclude the
patient. By pain or restricted movement during physical
examination, presence of both shoulder complaints and
dysfunction of the cervicothoracic spine and the adja-
cent ribs was confirmed. Eligible patients were 18 years
of age or older, and had had no consultation or treat-
ment for shoulder complaints in the past three months.
Reasons for exclusion were: acute severe trauma such as
fractures, ruptures or dislocation in the shoulder-region,
previous (orthopaedic) surgery in the shoulder region,
clear treatment preference deviating from study treat-
ments, contraindications for manipulative therapy (e.g.
hyper-mobility, instability or severe arthrosis of the cer-
vicothoracic spine), signs of cervical nerve root
compression, presence of specific rheumatic disorders,
presence of dementia or other severe psychiatric, emo-
tional or behavioural disorders, shoulder disorders due
to general internal thoracic and abdominal pathology
and inability to complete Dutch written questionnaires.
In the research centre the conducting researcher (GJDB)
verified the entry criteria before randomization by a
structured medical history and a physical assessment.
Patients were evenly allocated to either manipulative
therapy additional to usual medical care (UMC) or to
UMC alone after verification of eligibility and consent.
Thereafter, the researcher (GJDB) opened pre-prepared
numbered opaque sealed envelopes containing the treat-
ment allocation code from a randomization list pro-
duced by independent physician.
Interventions
All patients received usual medical care (UMC) from
their general practitioner (GP). All participating GPs
received training to apply UMC as encouraged by
Guidelines for Shoulder Complaints of the Dutch Col-
lege of General Practitioners [4]: during the first two
weeks information regarding the nature and the course
of shoulder complaints was given, together with advises
how to use the affected shoulder in daily living, supple-
mented with analgesics or NSAID’s if necessary. If lim-
ited effect ensued from this approach, up to 3
corticosteroid injections (in subacromial space or gleno-
humeral joint) could be given. Physiotherapy (9 treat-
ment sessions in a 3-months period) was considered for
complaints persisting for 6 weeks or more and consisted
of treatment of the shoulder with exercises, massage
and physical applications.
Additional manipulative therapy consisted of specific
manipulation techniques (high velocity, low amplitude
thrust) and mobilization techniques (passive low velocity
movements within the range of motion of the joint) of
the cervical spine, the upper thoracic spine and the
upper ribs on the segmental level and was aimed to
restore normal spinal function [12,13]. A maximum of 6
treatment sessions was given in a 12-weeks period.
Manipulative therapy was applied by 8 manual thera-
pists, who all are members of the Dutch Association of
Manual Therapy (NVMT), and were considered experi-
enced based on their previous case load.
Clinical Assessment
Outcome measures were assessed at baseline and at 6
weeks (during the intervention period), 12 weeks (at the
end of the intervention period), 26 and 52 weeks after
randomization. The primary outcome measure was
patient perceived recovery. Patients were considered
recovered if they reported being ‘completely recovered’
or ‘very much improved’ on a 7-point ordinal scale.
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plaint [14], shoulder pain [15], functional disability
[16,17] and general health [18]. Manual therapists as
well as general practitioners reported their treatment on
a standardized registration form.
Economic evaluation
Cost data were collected from a societal perspective,
using a cost diary that is considered valid and feasible
for patient completion [19]. The diary, covering a period
up to 6 weeks, was presented in a booklet form, con-
taining instructions and an example plus a telephone
number in case of questions. Patients were asked to
complete the cost diary up to 26 weeks follow-up. The
cost diary included direct health care costs: treatment
by a general practitioner, physiotherapist, manual thera-
pist, occupational therapist, exercise therapist (e.g. ‘Men-
sendieck’ or ‘Cesar’ therapist) or complementary health
therapists (e.g., acupuncturist), visits to a consultant in
orthopaedic surgery, neurology, rheumatology, or reha-
bilitation medicine, and professional home care and hos-
pitalization. Direct non-health related costs included out
of pocket expenses and costs for paid and unpaid help.
Indirect costs included loss of production due to sick
leave from paid and unpaid work. Indirect costs for paid
work were calculated using the friction cost method
[20,21], with a friction period of 123 days. Friction costs
were based on the mean income and sex of the Dutch
population [20,21]. We used a shadow price for unpaid
work of €8.60 per hour [20,21]. A complete overview of
the costs is given in the appendix (Additional file 1).
Medicine costs were based on the prices of the Royal
Dutch Society for Pharmacy [22].
Since participants had to visit the research centre for
the clinical follow-up measurements, cost diaries were
handed in at this time. A research-assistant checked the
cost diaries for incompleteness and asked the patient to
complete any missing data. During data check and qual-
ity control, standardized treatment registration forms
completed by the general practitioner and the physical
therapist were used for verification of cost data. How-
ever, when there was discrepancy between both infor-
mation sources, data from cost diaries was used.
Data analysis
Statistical analysis was performed blinded for treatment
allocation, according to the intention-to-treat principle
[23]. Clinical outcome measures were analyzed using a
paired samples t-test (two-sided a = 0.05). Differences
between groups with a 95% confidence interval were cal-
culated for each outcome measure. Extreme values and
outliers for clinical and cost data were identified and
their impact on the study outcome was explored.
The cost-effectiveness analysis was performed accord-
ing a protocol proposed by O’Brien and Briggs [24].
Bootstrapping was used to compare mean costs between
groups and to estimate 95% confidence intervals [25,26].
Incremental cost-effectiveness ratios, that is the ratio of
the difference in costs and the difference in effects
between the two treatments, were determined by boot-
strapping (2000 replications) according to the bias
corrected percentile method [27]. The bootstrapped
cost-effects pairs were graphically presented on a cost-
effectiveness plane [28]. Acceptability curves were
graphically reported to show the probability that a treat-
ment is cost-effective at a specific ceiling ratio [29].
We analyzed the trial data excluding patients with
missing cost data (intention-to-treat analysis). Further-
more, we conducted two adjusted analyses, once includ-
ing initially excluded patients after imputation
(replacement of missing cost data by the unconditional
means of the treatment group) and once excluding out-
liers with extremely high costs.
Role of the Funding Sources
Grant support was received from the Netherlands Orga-
nization for Scientific Research (904-65-901), and Foun-
dation ‘De Drie Lichten’. These funding organisations
approved the study design, but played no part in con-
ducting and reporting of the study.
Results
Patients
A total of 150 patients were included, of which 79
patients were allocatedt ot h eA M T - g r o u pa n d7 1
patients to the UMC-group, as shown in Figure 1. Table
1 shows their baseline data. Every patient had to com-
plete five cost diaries that together covered 26 weeks of
follow-up. In total, 645 of 750 (86%) of the cost diaries
were completed and returned (See Figure 1 for details).
Overall, 137 (91%) patients completed the clinical fol-
low-up measurement at 26 weeks. A total of eight
patients, six patients in the UMC-group and two
patients in the AMT-group did not return any of their
cost diaries and were their cost data were not imputed
in the intention-to-treat analysis. These patients were
generally characterized by a low mean age (42 years), a
short episode of complaints (<8 weeks), a gradual onset
of complaints, previous episodes of shoulder and neck
complaints, and by having paid jobs (n = 5). Also they
had more severe shoulder pain (mean 19 points) and
rated their shoulder disability (mean 77 points) as more
severe at baseline. Those patients with a similar prog-
nostic profile but with complete cost data, reported
higher total costs than patients with another prognostic
profile.
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In Table 2 the point estimates generally show that
manipulative treatment is effective as add-on to UMC.
During treatment (6 weeks) the clinical outcome mea-
sures favoured AMT in addition to UMC, but no signifi-
cant differences compared to UMC alone were found.
After completion of treatment (12 weeks), statistically
significant more patients receiving AMT reported full
recovery compared to patients receiving UMC (43% vs.
21%). At 12 weeks the difference in mean severity of
main complaint and shoulder pain also favoured manip-
ulative therapy. At 26 weeks after randomization, both
groups reported similar recovery rates (41% vs. 35%),
but the difference between groups in severity of main
complaint (Δ = 1.2, CI: 0.2 to 2.2), shoulder pain
(Δ = 0.7, CI: -1.0 to 2.5) and disability (Δ = 12.7, CI: 1.3
to 23.0) sustained.
Health care consumption and sick leave
The health care consumption by the two groups is pre-
sented in Table 3. The mean number of GP visits was
comparable between the two groups (1.5 visits AMT vs.
1.7 visits UMC). The mean number of unintended man-
ual therapy in patients receiving UMC was low (0.3 vis-
its), while the number of physiotherapy visits was higher
in the AMT group (4.3 sessions) compared to the UMC
group (2.0 sessions). Utilization of complementary
health therapies, care from medical consultants and hos-
pitalization were low in both groups. A difference was
found in help from friends and relatives. This was
mainly due to one patient allocated to AMT, who
received 30 hours professional home care per week, on
average for a 26 weeks period; this concerned continued
care from the pre-randomisation period. Furthermore, a
large difference between groups in sick leave from paid
work was found: 7 patients reported sick leave in the
UMC-group compared to 18 patients in the AMT-
group. In the latter group, two patients reported more
than 107 days of sick leave.
Costs
Patients who were recovered at 26 weeks after randomi-
zation showed lower costs compared to patients who
were not recovered (€429 vs. €1194). In patients recov-
ered at 26 weeks follow-up the total costs were lower
for patients who received AMT (€361;n = 32 vs. €508;n
= 25), while in patients not recovered at 26 weeks fol-
low-up the total costs were lower for patients who
received UMC (€584;n = 47, vs. €1137;n = 47).
The mean and standard deviations as well as mean
differences and their confidence intervals of the costs
for each intervention group are presented in Table 4.
Treatment by general practitioner and physiotherapist
accounted for 21% of the total costs in the UMC group
and for 6% in the AMT group. In addition the protoco-
lised manipulative therapy also represents 6% of the
total costs in the latter group. The total direct costs cost
were higher in patients who received AMT, but these
differences were not statistically significant. A large pro-
portion of the total costs are due to indirect costs (69%
for UMC-group vs. 78% for AMT-group). The large dif-
ference in indirect costs (€523) was for a considerable
part due to two patients allocated to AMT. These were
outliers with an average total cost of €18,408 per
patient.
Cost-effectiveness analyses
The cost-effectiveness ratios (CER) for the comparison
between AMT and UMC are presented in Table 5. The
Table 1 Baseline characteristics and values of outcome
measures by allocated treatment
AMT (n = 79) UMC (n = 71)
Mean age in years 48.4 ± 12.4 47.8 ± 11.8
Female 42 (51) 37 (52)
Dominant side affected 58 (73) 45 (63)
Acute onset of complaints 27 (35) 19 (28)
Mean duration before consultation
<6 weeks 28 (35) 28 (39)
6-12 weeks 25 (32) 22 (32)
12-26 weeks 10 (13) 11 (15)
>26 weeks 10 (14) 16 (20)
Previous episodes of shoulder pain
None 18 (23) 18 (25)
1 episode 18 (23) 14 (21)
2-5 episodes 27 (34) 27 (20)
>5 episodes 16 (20) 12 (17)
Previous neck complaints 50 (63) 43 (61)
Paid job 56/79 (71%) 47/71 (66%)
Previous sick leave from work
None 36/56 (46%) 37/47 (48%)
<2 weeks 17/56 (30%) 9/47 (19%)
>2 weeks 3/56 (5%) 4/47 (9%)
Severity of main complaint
a 6.9 ± 1.9 6.4 ± 2.1
Shoulder Pain
b 17.8 ± 4.7 17.9 ± 4.3
Shoulder Disability
c 58.6 ± 28.0 60.7 ± 29.0
General health (EQ5D)
d 0.69 ± .19 0.68 ± .18
Presented are number of patients and percentages between brackets [n (%)]
or mean scores and standard deviation [mean ± SD). AMT: Manipulative
therapy as add-on to UMC. UMC: Usual Medical Care by General Practitioner.
a) Severity of main complaint: rating by the patient for severity the main
complaint during the preceding week (11-point scale; 0(best) -10(worst)). b)
Shoulder Pain Score: rating by the patient for the experienced pain in rest,
pain in motion, nightly pain, sleeping problems caused by pain, incapability of
lying on the painful side, degree of radiation and general pain (all 4-point
ordinal scales; 1(no pain)- 4 (severe pain)), total range: 7(best)-28 worst). c)
Shoulder Disability Questionnaire: rating by the patient for the functional
status of the shoulder in the preceding 24 hours (16 items; not applicable/
yes/no). Presented score is the percentage of positive items in the total
applicable items, total range: 0(best)-100(worst). d) EuroQol: health related
quality of life (5 items; 3-point ordinal scale), total range: -1(worst)-+1(best).
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tal costs are €19,773 per patient to recover with AMT
after 26 weeks. The CER for shoulder disability shows
the lowest incremental costs for manipulative therapy
(€47 per unit improvement).
Figure 2 displays the cost-effectiveness plane for
patient perceived recovery. It represents 5000 replica-
tions of the CER for perceived recovery comparing the
two treatment modalities. Most cost-effect pairs are
concentrated around zero on the Y-axis, suggesting that
there is only a minor clinical effect, and above zero on
the X-axis, suggesting that treatment with AMT gener-
ates more costs than UMC alone. The other outcome
measures demonstrated a similar graph. However, as
shown in Table 3, the clinical effects for severity of
main complaint, shoulder pain and shoulder disability
are more prominent at 26 weeks after AMT than UMC.
The cost-effectiveness acceptability curves for patient
perceived recovery (Figure 3) show the probability that
manipulative therapy in addition to UMC is cost-effec-
tive at a certain cost ceiling ratio. For example, in the
unadjusted analysis the probability that AMT is cost-
effective is approximately 35% at a ceiling ratio of
€10,000. For patient perceived recovery, the 50%-prob-
ability corresponds with a ceiling ratio of €20,000. For
the other outcome measures, the 50%-probability of
cost-effectiveness is: €1150 for severity of main com-
plaint, €850 for severity of shoulder pain, €45 for sever-
ity of shoulder disability and €16,030 for general health.
Adjusted analyses
Besides the intention-to-treat analysis, two adjusted ana-
lyses were performed. In the first adjusted analysis the
missing cost data and clinical data of the eight excluded
patients were imputed. This analysis showed no impor-
tant differences from the analysis (no data presented). In
the second adjusted analysis, the two patients allocated
to AMT who generated extremely high costs due to sick
leave from work were excluded. Mainly due to lower
indirect costs this analysis showed a decrease of the dif-
ference in total costs between the intervention groups
from €612 to €121, whereby the cost-effectiveness ratio
for perceived recovery decreased from €19,773 to
€2,876, and the value of the ceiling ratio of 50%-prob-
ability that AMT is cost effective to recover one patient
after 26 weeks decreased from €20,000 to €2,800. Vice
versa, a ceiling ratio of €10,000 corresponds with a
Table 2 Principal outcomes at 12 weeks and 26 weeks
Outcome measure Mean effects Difference
AMT (n = 79) UMC (n = 71) (95%CI)
Perceived recovery (yes/no)
12 weeks 34/79 (43%) 15/71 (21%) 22% (6.9 to 35.4)
26 weeks 32/79 (41%) 25/71 (35%) 5% (-10.1 to 20.2)
Main complaint (0 -10.)
12 weeks 4.4 ± 3.0 2.9 ± 3.2 1.5 (0.5 to 2.5)
26 weeks 4.7 ± 3.4 3.5 ± 3.3 1.2 (0.2 to 2.2)
Shoulder pain (7 - 28)
12 weeks 5.7 ± 5.1 3.7 ± 5.2 2.0 (0.3 to 3.7)
26 weeks 5.9 ± 5.4 5.2 ± 5.5 0.7 (-1.0 to 2.5)
Shoulder disability (0 - 100)
12 weeks 26.6 ± 32.3 18.2 ± 32.4 8.5 (-2.0 to 18.9)
26 weeks 33.0 ± 34.6 20.3 ± 35.9 12.7 (1.3 to 24.1)
General Health (-1-+1)
12 weeks 0.09 ± 0.28 0.16 ± 0.25 -0.06 (-0.15 to 0.03)
26 weeks 0.11 ± 0.19 0.08 ± 0.21 0.03 (-0.04 to 0.09)
Presented are recovery rates and mean changes since baseline [± SD]). AMT: Manipulative therapy as add-on to Usual Medical Care. UMC: Usual Medical Care by
General Practitioner.
Table 3 Consumption of healthcare resources and sick
leave from work during a 26-weeks follow-up period
Type of utilization AMT (N = 77) UMC (N = 65)
General practice [no. of visits] 1.7 ± 2.7 1.5 ± 1.4
Manual therapist [no. of visits] * 3.7 ± 2.3 0.3 ± 1.2
Physiotherapist [no. of visits] 2.0 ± 6.0 4.3 ± 8.0
Alternative therapist [no. of visits] 0.1 ± 0.7 0.3 ± 1.5
Specialist care [no. of visits] 0.2 ± 1.0 0.2 ± 4.6
Hospitalization [days] 0.0 ± 0.0 0.0 ± 0.0
Home care [hours] 0.0 ± 0.0 0.2 ± 1.4
Help from friends and relatives [hours] 7.8 ± 46.4 1.2 ± 4.6
Sick leave from paid work [days] 5.8 ± 19.2 2.7 ±10.3
Sick leave from unpaid work [hours] 13.5 ± 67.3 2.5 ± 8.6
Presented are group means and standard deviations. AMT: Manipulative
therapy as add-on to UMC. UMC: Usual Medical Care by General Practitioner.
*Includes visits according the study protocol.
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analysis compared to 65% in the sensitivity analysis.
Discussion
Manipulative therapy of the cervicothoracic spine and the
adjacent ribs as add-on to usual medical care by the gen-
eral practitioner accelerates recovery of shoulder com-
plaints. The differences between AMT and UMC were
largest for recovery after 12 weeks (22%) and severity of
main complaint and shoulder disability after 26 weeks
(12% and 13%, respectively). However, AMT was asso-
ciated with higher costs than UMC. The balance between
costs and effects is markedly influenced by very few
extreme values for costs and few missing data. Adjust-
ment for these extremes cost outliers markedly changed
the balance between costs and effects: rather favourable
results (lower total costs) for AMT were obtained. Given
the large influence of these extreme values associated
with non-shoulder morbidity, we argue that the adjusted
analysis is justified and represent the cost-effectiveness
for AMT for shoulder complaints more accurately.
The higher costs of the manipulative therapy group
cannot completely be explained by the costs for the
AMT alone. The manipulative therapy (mean = 3.7 ses-
sions) accounts for €270, which explains 43% of the dif-
ference in total costs between both groups. Although
these differences were not statistically significant, the
AMT group generated higher costs on total health
related care as well as higher indirect costs than the
UMC-group. As expected, the direct health related care
costs were the highest during the intervention period.
The UMC treatment represents 21% of the total costs
for patients that received UMC only and 6% for patients
that received manipulative therapy in addition to UMC.
In the manipulative therapy group, only 6% of the total
costs were due to the standardized manipulative therapy.
The largest proportion of the total cost was due to sick
leave from work: 61% in patients that received UMC
only and 65% in patients that were allocated to manipu-
lative therapy.
S a m p l es i z ec a l c u l a t i o n sw e r en o tb a s e do nd e m o n -
strating cost-effectiveness. We needed 250 patients (125
in each treatment group) for sufficient statistical power
[30] to detect a clinically relevant difference of 20%
between groups, taken into account a recovery rate of
50% in the UMC group after 26 weeks, a two-sided
alpha of 0.05, a statistical power (1-b)o f0 . 8 0a n da n
attrition rate of 10%. An appropriately powered cost-
effectiveness study could require a much larger sample
size [31]. Although, because of constraints of time and
funding we included 150 patients with high adherence
to the allocated treatment and very limited attrition dur-
ing follow-up, clinically relevant effects have been found.
Moreover, due to adequate response and crosschecking
Table 4 Mean costs (in €) per treatment group and mean differences during a 26 week follow-up period
Costs AMT UMC AMT vs. UMC
Mean ± SD Mean difference (95%CI)
Total costs
Intention-to-treat (n = 142) 1167 ± 3348 555 ± 1290 612 (-193 to 1581)
Adjusted for outliers (n = 140) 676 ± 1445 555 ± 1290 121 (-340 to 581)
Total direct costs
Intention-to-treat (n = 142) 293 ± 602 192 ± 232 101 (-75 to 252)
Adjusted for outliers (n = 140) 266 ±555 192 ± 232 74 (-72 to 221)
Direct health care costs
Intention-to-treat (n = 142) 174 ± 190 153 ± 185 21 (-28 to 48)
Adjusted for outliers (n = 140) 166 ±180 153 ± 185 14 (-47 to 75)
Direct non-health care costs
Intention-to-treat (n = 142) 119 ± 468 39 ±119 80 (-25 to 191)
Adjusted for outliers (n = 140) 99 ± 436 39 ± 119 60 (-49 to 170)
Indirect costs
Intention-to-treat (n = 142) 913 ± 3091 381 ± 1222 523 (-338 to 1329)
Adjusted for outliers (n = 140) 446 ± 1138 381 ± 1222 66 (-329 to 460)
€:E u r o ’s( €1 = 1.20 US Dollars); AMT: Manipulative therapy as add-on to UMC. UMC: Usual Medical Care by General Practitioner.
Table 5 Cost-effectiveness ratios for clinical outcome
measures
Outcome measure AMT vs. UMC
Intention-to-treat Adjusted for outliers
Perceived recovery 19773 2876
Main complaint 1261 215
Shoulder pain 934 175
Shoulder disability 47 5
General health 16002 2952
AMT: Manipulative therapy as add-on to UMC. UMC: Usual Medical Care by
General Practitioner.
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set. We were unable to collect any of the cost diaries of
8 patients, of whom 6 received UMC alone and 2
received AMT. These 8 patients had a prognostic status
that is associated higher total costs. After imputation of
missing data and adjustment for extreme values, a rather
small difference in total costs between the groups
remained. Therefore, extreme and missing cost data
resulted in an underestimation of the cost-effectiveness
of manipulative treatment as an add-on to UMC.
This economic evaluation was based on the clinical
outcome at 26 weeks after randomization and therefore
did take into account the short-term improvement.
Since manipulative therapy aims to restore the function
of concurrent dysfunctions of the neck and high back,
which is an important prognostic indicator for shoulder
Figure 2 Cost-effectiveness plane for patient perceived recovery for manipulative therapy in addition to usual medical care by the GP
compared to usual medical care alone.
Figure 3 Cost-effectiveness acceptability curves for patient perceived recovery.
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Page 8 of 10disorders [32,33], we expected manipulative therapy to
be cost saving on the long term. Perhaps with a longer
follow-up more cost savings can be obtained. But our
follow-up for costs was limited to 6 months due to time
constraints. It is possible that prolonged and recurrent
pain episodes generate additional costs for more expen-
sive care, e.g. diagnostic imaging and surgical treatment,
including hospitalization.
The present study is the first to evaluate the cost-
effectiveness of a manipulative treatment in shoulder
complaints alongside a randomized trail. Korthals and
colleagues evaluated the cost effectiveness of physiother-
apy, manual therapy, and care by a general practitioner
for patients with neck pain in a randomized trial [34].
They concluded that manual therapy, (notably spinal
mobilization) was more effective and less costly for
treating neck pain than physiotherapy or care by a gen-
eral practitioner.
Conclusion
Our study shows that manipulative therapy in addition
to UMC accelerates recovery, is slightly more effective
on the long term, but is associated with higher costs
compared to UMC alone up to 26 weeks after initiation
of treatment. The balance between costs and effects was
markedly influenced by very few extreme values. After
adjustment for these extreme values the differences in
costs were small and, consequently, the extra costs for
one additional recovery relatively low.
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